Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Pragmatic Trial of a 6-Month Strategy for Rifampicin-Resistant Tuberculosis.

The New England journal of medicine·2026
Same author

Posttuberculosis Lung Disease in Adolescents in Lima, Peru.

Pediatrics·2026
Same author

Computer-aided detection for radiological disease severity classification on chest radiograph in children with intra-thoracic tuberculosis.

PLOS global public health·2026
Same author

Validation of treatment decision algorithms for childhood tuberculosis at district healthcare levels in Mozambique and Zambia: the Decide TB cluster-randomised pragmatic trial - a study protocol.

BMJ open·2026
Same author

Global, regional, and national estimates of tuberculosis incidence averted by eliminating undernutrition in adults: a modelling study.

The Lancet. Global health·2026
Same author

Lungs Are Only Half the Story: Programmatic Shifts to Prioritize Pediatric Extrapulmonary Tuberculosis Detection in High-Burden Settings.

Journal of the Pediatric Infectious Diseases Society·2026

Related Experiment Videos

Caring for children with drug-resistant tuberculosis: practice-based recommendations.

James A Seddon1, Jennifer J Furin, Marianne Gale

  • 1Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Clinical Building, Room 0085, Faculty of Medicine and Health Sciences, Stellenbosch University, PO Box 19063, Tygerberg, South Africa. jseddon@sun.ac.za

American Journal of Respiratory and Critical Care Medicine
|September 18, 2012
PubMed
Summary

Managing pediatric drug-resistant tuberculosis (DR-TB) is complex. This guidance synthesizes evidence and expert consensus to support clinicians in treating children with DR-TB effectively.

Related Experiment Videos

Area of Science:

  • Pediatric Infectious Diseases
  • Mycobacterial Research
  • Global Health

Background:

  • Drug-resistant tuberculosis (DR-TB) management in children presents unique challenges.
  • Limited evidence exists for optimal pediatric DR-TB treatment and follow-up protocols.
  • Current DR-TB guidelines often inadequately address pediatric-specific needs.

Framework:

  • This article provides practical guidance for pediatric DR-TB care.
  • It reviews existing literature, research studies, and international guidelines.
  • Expert consensus from experienced clinicians informs the recommendations.

Implementation:

  • Covers key aspects of pediatric DR-TB management: treatment initiation, regimen selection, and duration.
  • Addresses comorbid conditions, monitoring, and adverse event management.
  • Emphasizes adherence promotion and infection control within a multidisciplinary approach.

Implications:

  • Aims to bridge the evidence gap in pediatric DR-TB care.
  • Supports clinicians in diverse settings with varying resources.
  • Facilitates improved clinical decision-making and patient outcomes for children with DR-TB.